MARKET

BVXV

BVXV

BiondVax
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.966
-0.054
-1.78%
Opening 14:09 06/22 EDT
OPEN
3.000
PREV CLOSE
3.020
HIGH
3.042
LOW
2.851
VOLUME
96.06K
TURNOVER
--
52 WEEK HIGH
62.00
52 WEEK LOW
2.350
MARKET CAP
42.51M
P/E (TTM)
-6.4781
1D
5D
1M
3M
1Y
5Y
BiondVax Pharmaceuticals Ltd. (BVXV): Hedge Funds Are Snapping Up
Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to ...
Insider Monkey · 6d ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 06/08 20:48
BiondVax Pharmaceuticals FY21 EPS $(0.01) Down From $(0.00) YoY
BiondVax Pharmaceuticals (NASDAQ:BVXV) reported full year losses of $(0.01) per share. This is a 233.33 percent decrease over losses of $(0.00) per share from the same period last year.
Benzinga · 05/13 21:30
Biondvax Pharmaceuticals reports FY results
Biondvax Pharmaceuticals (BVXV): FY GAAP EPS of -$0.003.Cash and cash equivalents of $2.9MPress Release
Seekingalpha · 05/13 21:21
BiondVax Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
, /PRNewswire/ -- (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and ultimately commercializing products for the prevention and treatment of infectious diseases and related illnesses, today published its fourth quarter a...
PR Newswire - PRF · 05/13 20:54
Global All Vaccine Market Size 2021-2025 with Top-Countries Data And Covid-19 Analysis, Industry Size, Share, Business Growth, Revenue, Trends, Market Demand Penetration and Forecast
May 12, 2021 (The Expresswire) -- Global “All Vaccine Market” Report 20212025 covers the worldwide and regional market with an in-depth analysis ofthe...
The Express Wire · 05/12 06:06
Global Influenza Vaccines Market Report 2021-2027 - Chinese Market is Expected to Record a Value of Nearly $180 Million
Dublin, May 05, May 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Global Influenza Vaccines Market 2021 - 2027"...
GlobeNewswire · 05/05 10:13
All Vaccine Market Top Key Players Analysis by Growth Overview 2021: Trending Technologies, CAGR Status, Business Prospects, Share, Trends, SWOT Analysis, and Forecast to 2026
May 03, 2021 (The Expresswire) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." The “All Vaccine Market” Research Report...
The Express Wire · 05/03 08:11
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BVXV. Analyze the recent business situations of BiondVax through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BVXV stock price target is 81.00 with a high estimate of 81.00 and a low estimate of 81.00.
EPS
Institutional Holdings
Institutions: 24
Institutional Holdings: 311.26K
% Owned: 2.17%
Shares Outstanding: 14.33M
TypeInstitutionsShares
Increased
1
6.80K
New
9
134.01K
Decreased
3
51.86K
Sold Out
3
27.20K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.33%
Pharmaceuticals & Medical Research
-0.52%
Key Executives
Chairman/Director
Mark Germain
Chief Executive Officer/President/Director
Ron Babecoff
Chief Financial Officer
Uri Ben-Or
Chief Scientific Officer
Tamar Ben-Yedidia
Other
Yisrael Gewirtz
Director
George Lowell
Director
Yael Margolin
Director
Samuel Moed
Director
Adi Raviv
Director
Jack Rosen
Director
Avner Rotman
Non-Executive Director
Irit Ben-Ami
Independent Director
Ruth Ben Yakar
No Data
  • All
  • Financials
  • Insiders
More
About BVXV
BiondVax Pharmaceuticals Ltd is an Israel-based is Phase 3 clinical phase biopharmaceutical company. It is developing the M-001 Universal Flu Vaccine. M-001 is undergoing a pivotal, clinical efficacy, Phase 3 trial in about 12,400 participants. M-001 is designed to provide multi-season and multi-strain protection against all human influenza virus strains, both seasonal and pandemic. In 6 completed clinical trials the vaccine was shown to be safe, well tolerated and immunogenic to a broad range of flu strains. The Company’s technology utilizes a proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.

Webull offers kinds of Biondvax Pharmaceuticals Ltd - ADR stock information, including NASDAQ:BVXV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BVXV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BVXV stock methods without spending real money on the virtual paper trading platform.